Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis

Mark Lebwohl, Stephen Sacks, Marcus Conant, James Connor, John M. Douglas, Lawrence Eron, Steven Marlowe, Jack Mendelson, Virginia Chen, Patricia Bradstreet, David Fedorczyk, J. Richard Trout, Terry Plasse

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Topical recombinant alpha-2 interferon treatment of recurrent genital herpes was studied in a randomized, double-blind, placebo controlled clinical trial. Three hundred and eighty-seven patients were treated at eight study centers with either interferon gel or placebo four times daily for four days. Interferon therapy caused a 26% decrease in the duration of viral shedding. For male patients, there were also significant decreases in the time to crusting (17%) and duration of pain (34%) and itching (21%). For patients with recurrent genital herpes, treatment with topical interferon was found to be effective in decreasing the duration of viral shedding and, for males, pain, itching and time to crusting.

Original languageEnglish
Pages (from-to)235-243
Number of pages9
JournalAntiviral Research
Issue number3
StatePublished - Mar 1992


  • Herpes genitalis
  • Interferon
  • Topical


Dive into the research topics of 'Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis'. Together they form a unique fingerprint.

Cite this